Vitamin a derivative takes on tough lymphoma

NCT ID NCT04234048

Recruiting now Disease control Sponsor: SciTech Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, then testing that dose in a larger group to see how well it works. About 46 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fenretinide (a form of vitamin A) given as an intravenous infusion
What this could lead to: If it works, this could point toward a new treatment option for people with T-cell lymphoma that has not responded to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 46 participants, so it is primarily testing safety and dosing. It may not show enough benefit to move forward, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioimmunoblastic T-cell lymphoma lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified primary cutaneous anaplastic large cell lymphoma primary cutaneous T-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA CUTANEOUS T-CELL LYMPHOMA CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED CUTANEOUS/PERIPHERAL T-CELL LYMPHOMA FOLLICULAR T-CELL LYMPHOMA MYCOSIS FUNGOIDES PERIPHERAL T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA, NOT CLASSIFIED PRIMARY CUTANEOUS T-CELL LYMPHOMA SÉZARY'S DISEASE T-CELL LYMPHOMA

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute Wayne State University
RECRUITING

Detroit, Michigan, 48201, United States
City of Hope Medical Foundation
RECRUITING

Duarte, California, 91010, United States
Columbia University
RECRUITING

New York, New York, 10032, United States
Mayo Clinic Arizona
RECRUITING

Scottsdale, Arizona, 85259, United States
Northwestern University, Robert H. Lurie Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60611, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Colorado Anschutz Medical Campus
RECRUITING

Aurora, Colorado, 80045, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh Medical Center (UPMC)
RECRUITING

Pittsburgh, Pennsylvania, 15219, United States
University of Southern California
RECRUITING

Los Angeles, California, 90007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.